NRTX-1001 is under clinical development by Neurona Therapeutics and currently in Phase II for Epilepsy. According to GlobalData, Phase II drugs for Epilepsy have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NRTX-1001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NRTX-1001 overview

NRTX-1001 is under development for the treatment of neuropathic pain, phencyclidine-induced cognitive deficits, chronic mesial temporal lobe epilepsy, Parkinson's disease and Alzheimer's disease. The therapy consists of medial ganglionic eminence (MGE) cells that are derived from human embryonic stem (ES) cells. It is administered through parenteral route for the treatment of epilepsy.

Neurona Therapeutics overview

Neurona Therapeutics is a pre-clinical stage biotechnology company providing cell-based medicines dealing with neurological disorders. Neurona Therapeutics is headquartered in South San Francisco, California, the US.

For a complete picture of NRTX-1001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.